New‐onset posttransplant diabetes mellitus after haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide
Abstract Haploidentical hematopoietic cell transplantation (haplo‐HCT) with posttransplant cyclophosphamide (PTCY) is utilized for patients with hematological disorders but without conventional donors. The effects of new‐onset posttransplant diabetes mellitus (PTDM) following haplo‐HCT are unknown....
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-11-01
|
| Series: | eJHaem |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jha2.70 |
| _version_ | 1797739986959728640 |
|---|---|
| author | Brendan L. Mangan Dilan Patel Heidi Chen Katie S. Gatwood Michael T. Byrne Salyka Sengsayadeth Stacey Goodman Bhagirathbhai Dholaria Adetola A. Kassim Madan Jagasia Wichai Chinratanalab Kathryn A. Culos Brian G. Engelhardt |
| author_facet | Brendan L. Mangan Dilan Patel Heidi Chen Katie S. Gatwood Michael T. Byrne Salyka Sengsayadeth Stacey Goodman Bhagirathbhai Dholaria Adetola A. Kassim Madan Jagasia Wichai Chinratanalab Kathryn A. Culos Brian G. Engelhardt |
| author_sort | Brendan L. Mangan |
| collection | DOAJ |
| description | Abstract Haploidentical hematopoietic cell transplantation (haplo‐HCT) with posttransplant cyclophosphamide (PTCY) is utilized for patients with hematological disorders but without conventional donors. The effects of new‐onset posttransplant diabetes mellitus (PTDM) following haplo‐HCT are unknown. We examined PTDM incidence and outcomes after haplo‐HCT with PTCY. Patients without diabetes receiving haplo‐HCT (n = 64) were analyzed for PTDM diagnosis (defined as blood glucose ≥ 200 mg/dL). By day 100, 14 (22%) patients developed PTDM (median, 18 days). Hyperglycemia (blood glucose ≥ 200 mg/dL) preceded corticosteroids in 11 (79%) individuals. PTDM patients had increased death/relapse (P = .029). PTDM occurs frequently, precedes corticosteroids, and leads to inferior outcomes following haplo‐HCT. PTDM prophylaxis/treatment may improve HCT survival. |
| first_indexed | 2024-03-12T14:06:03Z |
| format | Article |
| id | doaj.art-c10492381e0a4e2f84e708a1430bb2ac |
| institution | Directory Open Access Journal |
| issn | 2688-6146 |
| language | English |
| last_indexed | 2024-03-12T14:06:03Z |
| publishDate | 2020-11-01 |
| publisher | Wiley |
| record_format | Article |
| series | eJHaem |
| spelling | doaj.art-c10492381e0a4e2f84e708a1430bb2ac2023-08-21T14:10:56ZengWileyeJHaem2688-61462020-11-011257658010.1002/jha2.70New‐onset posttransplant diabetes mellitus after haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamideBrendan L. Mangan0Dilan Patel1Heidi Chen2Katie S. Gatwood3Michael T. Byrne4Salyka Sengsayadeth5Stacey Goodman6Bhagirathbhai Dholaria7Adetola A. Kassim8Madan Jagasia9Wichai Chinratanalab10Kathryn A. Culos11Brian G. Engelhardt12Department of Pharmacy Vanderbilt University Medical Center Nashville TennesseeDivision of Hematology and Oncology Department of Medicine Vanderbilt University Medical Center Nashville TennesseeDepartment of Biostatistics Vanderbilt University Medical Center Nashville TennesseeDepartment of Pharmacy Vanderbilt University Medical Center Nashville TennesseeDivision of Hematology and Oncology Department of Medicine Vanderbilt University Medical Center Nashville TennesseeDivision of Hematology and Oncology Department of Medicine Vanderbilt University Medical Center Nashville TennesseeDivision of Hematology and Oncology Department of Medicine Vanderbilt University Medical Center Nashville TennesseeDivision of Hematology and Oncology Department of Medicine Vanderbilt University Medical Center Nashville TennesseeDivision of Hematology and Oncology Department of Medicine Vanderbilt University Medical Center Nashville TennesseeDivision of Hematology and Oncology Department of Medicine Vanderbilt University Medical Center Nashville TennesseeDivision of Hematology and Oncology Department of Medicine Vanderbilt University Medical Center Nashville TennesseeDepartment of Pharmacy Vanderbilt University Medical Center Nashville TennesseeDivision of Hematology and Oncology Department of Medicine Vanderbilt University Medical Center Nashville TennesseeAbstract Haploidentical hematopoietic cell transplantation (haplo‐HCT) with posttransplant cyclophosphamide (PTCY) is utilized for patients with hematological disorders but without conventional donors. The effects of new‐onset posttransplant diabetes mellitus (PTDM) following haplo‐HCT are unknown. We examined PTDM incidence and outcomes after haplo‐HCT with PTCY. Patients without diabetes receiving haplo‐HCT (n = 64) were analyzed for PTDM diagnosis (defined as blood glucose ≥ 200 mg/dL). By day 100, 14 (22%) patients developed PTDM (median, 18 days). Hyperglycemia (blood glucose ≥ 200 mg/dL) preceded corticosteroids in 11 (79%) individuals. PTDM patients had increased death/relapse (P = .029). PTDM occurs frequently, precedes corticosteroids, and leads to inferior outcomes following haplo‐HCT. PTDM prophylaxis/treatment may improve HCT survival.https://doi.org/10.1002/jha2.70haploidenticalhematopoietic cell transplantposttransplant diabetes mellitus |
| spellingShingle | Brendan L. Mangan Dilan Patel Heidi Chen Katie S. Gatwood Michael T. Byrne Salyka Sengsayadeth Stacey Goodman Bhagirathbhai Dholaria Adetola A. Kassim Madan Jagasia Wichai Chinratanalab Kathryn A. Culos Brian G. Engelhardt New‐onset posttransplant diabetes mellitus after haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide eJHaem haploidentical hematopoietic cell transplant posttransplant diabetes mellitus |
| title | New‐onset posttransplant diabetes mellitus after haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide |
| title_full | New‐onset posttransplant diabetes mellitus after haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide |
| title_fullStr | New‐onset posttransplant diabetes mellitus after haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide |
| title_full_unstemmed | New‐onset posttransplant diabetes mellitus after haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide |
| title_short | New‐onset posttransplant diabetes mellitus after haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide |
| title_sort | new onset posttransplant diabetes mellitus after haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide |
| topic | haploidentical hematopoietic cell transplant posttransplant diabetes mellitus |
| url | https://doi.org/10.1002/jha2.70 |
| work_keys_str_mv | AT brendanlmangan newonsetposttransplantdiabetesmellitusafterhaploidenticalhematopoieticcelltransplantationwithposttransplantcyclophosphamide AT dilanpatel newonsetposttransplantdiabetesmellitusafterhaploidenticalhematopoieticcelltransplantationwithposttransplantcyclophosphamide AT heidichen newonsetposttransplantdiabetesmellitusafterhaploidenticalhematopoieticcelltransplantationwithposttransplantcyclophosphamide AT katiesgatwood newonsetposttransplantdiabetesmellitusafterhaploidenticalhematopoieticcelltransplantationwithposttransplantcyclophosphamide AT michaeltbyrne newonsetposttransplantdiabetesmellitusafterhaploidenticalhematopoieticcelltransplantationwithposttransplantcyclophosphamide AT salykasengsayadeth newonsetposttransplantdiabetesmellitusafterhaploidenticalhematopoieticcelltransplantationwithposttransplantcyclophosphamide AT staceygoodman newonsetposttransplantdiabetesmellitusafterhaploidenticalhematopoieticcelltransplantationwithposttransplantcyclophosphamide AT bhagirathbhaidholaria newonsetposttransplantdiabetesmellitusafterhaploidenticalhematopoieticcelltransplantationwithposttransplantcyclophosphamide AT adetolaakassim newonsetposttransplantdiabetesmellitusafterhaploidenticalhematopoieticcelltransplantationwithposttransplantcyclophosphamide AT madanjagasia newonsetposttransplantdiabetesmellitusafterhaploidenticalhematopoieticcelltransplantationwithposttransplantcyclophosphamide AT wichaichinratanalab newonsetposttransplantdiabetesmellitusafterhaploidenticalhematopoieticcelltransplantationwithposttransplantcyclophosphamide AT kathrynaculos newonsetposttransplantdiabetesmellitusafterhaploidenticalhematopoieticcelltransplantationwithposttransplantcyclophosphamide AT briangengelhardt newonsetposttransplantdiabetesmellitusafterhaploidenticalhematopoieticcelltransplantationwithposttransplantcyclophosphamide |